Bird – Talk Bio

Endpoints 11: Biopharma’s most promising startups revealed live in Boston this September

1 month ago talkbio0Tagged Aves, Biopharma, biotech startups, biotechs, Boston event, Endpoints, GALA peptide, Industry, Rating (action), real-time, State Room

Endpoints 11; biotech startups; biopharma; Boston event; State Room; awards gala; early bird rate; industry insiders; 2025 most promising biotechs; real-time reveal

Royalty Market Accelerates with XOMA Biotech Acquisitions and OrbiMed’s Major Fundraise

1 month ago talkbio0Tagged Arenaria, Biological Factors, Biological Science Disciplines, biopharma financing, Conditional, HilleVax, Investments, LAVA, M&A, mezigitamab, OrbiMed, royalty acquisition, XOMA Royalty

royalty acquisition; XOMA Royalty; biotech M&A; OrbiMed; biopharma financing; mezigitamab; Turnstone Biologics; HilleVax; LAVA Therapeutics; contingent value rights; life sciences investment

Trump Administration Unveils Health Data Sharing Scheme Backed by Apple, Amazon, and Others

1 month ago talkbio0Tagged Administration occupational activities, Amazona, CMS Interoperability Framework, digital health records, Genus Malus, health data, Privacy, tech partnerships, Transplant Registry Unified Management Program

Trump administration; health data sharing; CMS Interoperability Framework; Apple; Amazon; digital health records; patient data; privacy; tech partnerships

Merck Terminates Midstage Asset from $1.9B Pandion Acquisition over Lack of Clinical Benefit

1 month ago talkbio0Tagged asset termination, Benefit, biotech acquisition, Clinical Trials, lack of, Merck, Pandion

Merck; Pandion Therapeutics; asset termination; clinical trial; lack of benefit; biotech acquisition

Bluebird Private Equity Buyout Boosts Upfront Cash for Shareholders

4 months ago talkbio0Tagged Capital, Carlyle, contingent value right, CVR, DKK1 gene, Family Turdidae (organism), Merger, Private Equity, shareholders, upfront cash

Bluebird; private equity buyout; shareholders; upfront cash; Carlyle; SK Capital; contingent value right; CVR; buyout terms; merger

Generation Gold Standard: HHS’s $500 Million Initiative for Universal Vaccine Development

4 months ago talkbio0Tagged Bhattacharya, BPL, Genus: Coronavirus, Jay, NIH Mouse, pandemic preparedness, propiolactone, Universal, Vaccines, whole-virus

Universal vaccines, beta-propiolactone (BPL), whole-virus platform, influenza, coronavirus, NIH, Jay Bhattacharya, Robert F. Kennedy Jr., pandemic preparedness

Novartis bolsters renal disease pipeline with $1.7B deal for Regulus

4 months ago talkbio0Tagged farabursen, Goldcrest, Novartis

Goldcrest, farabursen, Novartis

Novartis to buy Regulus Therapeutics for up to $1.7B

4 months ago talkbio0Tagged Acquisition (action), Goldcrest, Kidney Diseases, Novartis

Goldcrest, Novartis, Acquisition (action), Kidney Diseases

Ayrmid misses deadline for detailed offer to top private equity bid for bluebird

5 months ago talkbio0Tagged Ayrmid, Capital, deadline, Failed, Family Turdidae (organism), gene therapy, Private Equity, proposal - intent, United States Food and Drug Administration

Ayrmid, Family Turdidae (organism), gene therapy, Failed, Capital, proposal – intent, United States Food and Drug Administration, private equity, deadline

Bluebird bio receives rival M&A bid worth 50% higher than Carlyle-SK offer

5 months ago talkbio0Tagged Ayrmid, Bluebird Bio, Capital, Carlyle, Family Turdidae (organism), gene therapy, High, Twice a day

Ayrmid, Family Turdidae (organism), Twice a day, gene therapy, Carlyle, High, Bluebird Bio, Capital